HRP20030125B1 - Prodrugs to nmda receptor ligands - Google Patents

Prodrugs to nmda receptor ligands

Info

Publication number
HRP20030125B1
HRP20030125B1 HR20030125A HRP20030125A HRP20030125B1 HR P20030125 B1 HRP20030125 B1 HR P20030125B1 HR 20030125 A HR20030125 A HR 20030125A HR P20030125 A HRP20030125 A HR P20030125A HR P20030125 B1 HRP20030125 B1 HR P20030125B1
Authority
HR
Croatia
Prior art keywords
lower alkyl
prodrugs
nmda receptor
receptor ligands
ylid
Prior art date
Application number
HR20030125A
Other languages
English (en)
Croatian (hr)
Inventor
Alanine Alexander
Buettelmann Bernd
Fisher Holger
Heitz Neidhart Marie-Paule
Huwyler Joerg
Jaeschke Georg
Pinard Emmanuel
Wyler Rene
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20030125A2 publication Critical patent/HRP20030125A2/hr
Publication of HRP20030125B1 publication Critical patent/HRP20030125B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20030125A 2000-08-21 2001-08-20 Prodrugs to nmda receptor ligands HRP20030125B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00117918 2000-08-21
PCT/EP2001/009561 WO2002016321A1 (en) 2000-08-21 2001-08-20 Prodrugs to nmda receptor ligands

Publications (2)

Publication Number Publication Date
HRP20030125A2 HRP20030125A2 (en) 2005-02-28
HRP20030125B1 true HRP20030125B1 (en) 2011-07-31

Family

ID=8169594

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030125A HRP20030125B1 (en) 2000-08-21 2001-08-20 Prodrugs to nmda receptor ligands

Country Status (35)

Country Link
US (1) US6407235B1 (https=)
EP (1) EP1313703B1 (https=)
JP (1) JP4162991B2 (https=)
KR (1) KR100589991B1 (https=)
CN (1) CN1227230C (https=)
AR (1) AR030373A1 (https=)
AT (1) ATE386022T1 (https=)
AU (2) AU8589401A (https=)
BR (1) BR0113348A (https=)
CA (1) CA2419279C (https=)
CY (1) CY1107937T1 (https=)
CZ (1) CZ303319B6 (https=)
DE (1) DE60132782T2 (https=)
DK (1) DK1313703T3 (https=)
EC (1) ECSP034489A (https=)
EG (1) EG24293A (https=)
ES (1) ES2299508T3 (https=)
HR (1) HRP20030125B1 (https=)
HU (1) HU229802B1 (https=)
IL (1) IL154254A0 (https=)
JO (1) JO2289B1 (https=)
MA (1) MA26947A1 (https=)
MX (1) MXPA03001311A (https=)
MY (1) MY136065A (https=)
NO (1) NO324941B1 (https=)
NZ (1) NZ523990A (https=)
PA (1) PA8525601A1 (https=)
PE (1) PE20020291A1 (https=)
PL (1) PL204215B1 (https=)
PT (1) PT1313703E (https=)
RS (1) RS51467B (https=)
RU (1) RU2272027C2 (https=)
SI (1) SI1313703T1 (https=)
WO (1) WO2002016321A1 (https=)
ZA (1) ZA200300894B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1265864A1 (en) * 2000-03-21 2002-12-18 The Procter & Gamble Company Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
CA2633010A1 (en) * 2005-12-19 2007-06-28 Methylgene Inc. Histone deacetylase inhibitors for enhancing activity of antifungal agents
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
EP1973872A4 (en) 2006-12-19 2012-05-09 Methylgene Inc HISTONDEACETYLASE HEMMER AND PROPHARMAKA THEREOF
PL4001272T3 (pl) 2013-11-05 2025-02-10 Astrazeneca Ab Proleki antagonisty nmda

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0824098A1 (en) * 1996-07-19 1998-02-18 F. Hoffmann-La Roche Ag 4-hydroxy-piperidine derivatives
WO2000075109A1 (en) * 1999-06-08 2000-12-14 F. Hoffmann-La Roche Ag Ethanesulfonyl-piperidine derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1048247C (zh) * 1994-01-31 2000-01-12 美国辉瑞有限公司 神经保护的苯并二氢吡喃化合物
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0824098A1 (en) * 1996-07-19 1998-02-18 F. Hoffmann-La Roche Ag 4-hydroxy-piperidine derivatives
WO2000075109A1 (en) * 1999-06-08 2000-12-14 F. Hoffmann-La Roche Ag Ethanesulfonyl-piperidine derivatives

Also Published As

Publication number Publication date
KR100589991B1 (ko) 2006-06-15
US6407235B1 (en) 2002-06-18
JO2289B1 (en) 2005-09-12
CY1107937T1 (el) 2013-09-04
RS51467B (sr) 2011-04-30
NO324941B1 (no) 2008-01-07
HU229802B1 (hu) 2014-07-28
HRP20030125A2 (en) 2005-02-28
JP4162991B2 (ja) 2008-10-08
ES2299508T3 (es) 2008-06-01
PE20020291A1 (es) 2002-04-17
DE60132782T2 (de) 2009-02-05
SI1313703T1 (sl) 2008-06-30
CZ303319B6 (cs) 2012-08-01
MY136065A (en) 2008-08-29
PL204215B1 (pl) 2009-12-31
NO20030781D0 (no) 2003-02-19
EP1313703A1 (en) 2003-05-28
AR030373A1 (es) 2003-08-20
KR20030022417A (ko) 2003-03-15
PT1313703E (pt) 2008-03-25
AU2001285894B2 (en) 2006-06-15
EG24293A (en) 2009-01-08
BR0113348A (pt) 2003-07-08
DK1313703T3 (da) 2008-05-19
ATE386022T1 (de) 2008-03-15
MXPA03001311A (es) 2003-06-30
EP1313703B1 (en) 2008-02-13
HUP0301548A2 (hu) 2003-08-28
AU8589401A (en) 2002-03-04
IL154254A0 (en) 2003-09-17
DE60132782D1 (de) 2008-03-27
CN1227230C (zh) 2005-11-16
YU13003A (sh) 2006-05-25
HK1059083A1 (en) 2004-06-18
CA2419279C (en) 2008-10-14
MA26947A1 (fr) 2004-12-20
CZ2003492A3 (cs) 2004-01-14
NO20030781L (no) 2003-02-19
PA8525601A1 (es) 2002-04-25
JP2004506715A (ja) 2004-03-04
US20020040037A1 (en) 2002-04-04
WO2002016321A1 (en) 2002-02-28
ZA200300894B (en) 2004-04-30
ECSP034489A (es) 2003-03-31
RU2272027C2 (ru) 2006-03-20
CA2419279A1 (en) 2002-02-28
PL361387A1 (en) 2004-10-04
NZ523990A (en) 2004-09-24
CN1447793A (zh) 2003-10-08
HUP0301548A3 (en) 2010-03-29

Similar Documents

Publication Publication Date Title
ID17851A (id) Persenyawaan heterosiklis, produksi dan pemakaiannya
ATE209645T1 (de) Neue verbindung, verfahren zu ihrer herstellung und antitumormittel
CO4750662A1 (es) DERIVADOS DE BENZO (g) QUINOLINA
AR049401A1 (es) Aza-biciclononanos
IL180428A0 (en) Novel flame-retardant polystyrenes
TW200745153A (en) Trehalose compound and pharmaceutical comprising the compound
HRP20030125B1 (en) Prodrugs to nmda receptor ligands
MXPA02012569A (es) Ftalidas substituidas novedosas, un procedimiento para su preparacion y las composiciones farmaceuticas que contienen a las mismas.
TNSN07395A1 (en) Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives
IS6452A (is) Ný tetrahýdrópýridín, framleiðsluaðferð og lyfjasamsetningar sem innihalda þau
HUP9801089A2 (hu) Benzolszulfonamidszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
HRP20031055B1 (hr) Novi imunomodulirajući spojevi
MY125037A (en) 1,2,3,4 tetrahydroquinoline derivatives
ATE148128T1 (de) Anthracyclinglycosid-derivate und verfahren zu ihrer herstellung
CA2364199A1 (fr) Nouveaux derives bicycliques d'amino-pyrazinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MEP12408A (en) Acyloxypyrrolidine derivatives and use thereof as ligands of v1b or both v1b and v1a receptors
EA200000598A1 (ru) Новые ингибиторы металлопротеазы, способ их получения и содержащие их фармацевтические композиции
EP1403250A4 (en) Bis (5-aryl-2-pyridyl) DERIVATIVES
FR2826005B1 (fr) Synthese totale de la galanthamine, de ses analogues et de ses derives
BR0113907A (pt) Derivados bifenilas substituìdos, o respectivo processo de preparação e as composições farmacêuticas que os contêm
MY132324A (en) New piperazine derivatives and methods for the preperation thereof and compositions containing the same
BR0115809A (pt) Processo de ciclização para sìntese de compostos derivados de pirolidina
DK480389A (da) Antitumor-aktivt derivat af sf2587, fremgangsmaade til det fremstilling og anticancermiddel indeholdende stoffet
IL74877A0 (en) 9-halogen prostaglandin derivatives,process for the preparation thereof and pharmaceutical compositions containing the same
MX9603308A (es) Nuevos derivados piperazina y metodos para su preparacion y composicion que los contiene.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: EVOTEC INTERNATIONAL GMBH, DE

ODRP Renewal fee for the maintenance of a patent

Payment date: 20140728

Year of fee payment: 14

PBON Lapse due to non-payment of renewal fee

Effective date: 20150820